A New Era for Gluten Safety: Global Codex Standards Set to Transform Allergen Labeling

In a landmark move for the global celiac disease community, the 49th Session of the Codex Committee on Food Labelling (CCFL49) has officially forwarded updated guidance for precautionary allergen labeling (PAL) to be adopted as an international standard. This development marks a pivotal shift in how food manufacturers manage and communicate the risk of gluten cross-contact, moving away from vague, confusing warnings toward a rigorous, science-based framework.

For the millions of people living with celiac disease worldwide, this update represents the culmination of years of advocacy, clinical research, and international cooperation. Most notably, it establishes a formal reference dose for gluten—a tool that allows for consistent, data-driven risk assessment, while firmly maintaining the established 20 parts per million (ppm) “gluten-free” standard.

---

Main Facts: What Has Changed?

The core of this regulatory advancement is the introduction of a 4 mg reference dose for gluten. It is crucial to distinguish this from a consumer-facing instruction; the 4 mg figure is a scientific benchmark used by food safety experts to calculate "action levels."

Key Takeaways:

• The 4 mg Reference Dose: This is the amount of gluten that, if consumed, is unlikely to cause adverse reactions in the majority of celiac patients. It serves as the baseline for determining when a “may contain” warning is scientifically warranted.
• Preserving the 20 ppm Standard: The update does not weaken or replace the existing 20 ppm gluten-free threshold. Products labeled “gluten-free” must still meet this standard, which remains the gold-standard for safety.
• Risk-Based, Not Fear-Based: The new guidance encourages manufacturers to use “may contain” statements only when a formal risk assessment indicates that gluten cross-contact cannot be sufficiently mitigated. This is designed to reduce the "crying wolf" effect of excessive, vague warnings that currently plague grocery store shelves.
• Beyond Wheat Allergy: Historically, PAL guidance was largely driven by wheat allergy standards. This new framework recognizes that celiac disease is triggered by a broader spectrum of grains—wheat, barley, and rye—and requires an evaluation of the cumulative, long-term impact of gluten exposure.

---

A Chronology of Advocacy: The Path to CCFL49

The path to this international consensus was neither short nor simple. It required a concerted effort to align clinical science with international regulatory policy.

2018–2022: Building the Foundation

The Celiac Disease Foundation began its formal involvement in international standard-setting by becoming the North American representative to the Association of European Coeliac Societies (AOECS). This relationship allowed the Foundation to pool resources and align messaging with European experts who had been at the forefront of gluten safety research.

2023: The CCFL48 Turning Point

At the 48th Session of the Codex Committee on Food Labelling (CCFL48) in Quebec City, the Celiac Disease Foundation secured a seat on the U.S. delegation. This was a defining moment, as it allowed the Foundation to present data directly to regulators, arguing that gluten cross-contact is a distinct issue that cannot be managed through the lens of wheat allergy alone.

2024: The Scientific Deep Dive

Following the momentum of CCFL48, the Foundation urged the International Society for the Study of Celiac Disease (ISSCD) to convene the Gluten Safety Standards Committee (GSSC). This committee brought together world-renowned clinicians and scientists to define the technical parameters of the 4 mg reference dose. Simultaneously, the Foundation convened the Global Celiac Advocacy Alliance, ensuring that patient voices were unified across international borders.

2025–2026: The Final Push

Through participation in FAO/WHO meetings and persistent lobbying for science-based policy, the Foundation saw its efforts bear fruit at CCFL49. The committee’s decision to move the guidance forward for final adoption signals that the international regulatory community has accepted the necessity of a dedicated gluten safety framework.

---

Supporting Data: Why a Reference Dose Matters

The primary challenge in managing celiac disease is not just the presence of gluten, but the variability of cross-contact. Current labeling practices often result in products that carry warnings such as "processed in a facility that also processes wheat." While meant to protect consumers, these statements are often overused, depriving celiac patients of safe food choices and creating "label fatigue."

The Calculation of Risk

The new guidance utilizes the 4 mg reference dose to create an "action level." An action level is food-specific; it accounts for the typical serving size of a product. If a manufacturer determines that the amount of gluten in a single serving exceeds the action level, and they cannot reduce that risk through cleaning or separation, then a "may contain" statement becomes the appropriate, transparent choice.

This approach provides two distinct benefits:

1. Reduced Ambiguity: It discourages "blanket" warnings that serve as legal shields for manufacturers rather than safety tools for consumers.
2. Increased Transparency: It forces a higher standard of internal risk management, where companies must justify the use of precautionary labels with actual data rather than generic facility descriptions.

---

Official Responses and Stakeholder Impact

The response from the scientific and patient advocacy communities has been overwhelmingly positive, though stakeholders emphasize that the work is far from over.

"This is the culmination of years of tireless work," said Marilyn Geller, CEO of the Celiac Disease Foundation. "By moving toward a risk-based framework, we are finally treating gluten cross-contact with the scientific rigor it deserves. This isn’t just about labels; it’s about giving patients the confidence to navigate their lives without the constant fear of the unknown."

International partners, including the AOECS, have echoed this sentiment, noting that the Codex adoption will serve as a powerful tool to pressure national governments to update their own labeling laws. However, the scientific community cautions that implementation will require time. Manufacturers will need to undergo training to perform the necessary risk assessments, and regulatory bodies must integrate these new guidelines into their existing inspection protocols.

---

Implications for the United States: A Roadmap for the FDA

The United States occupies a unique position in this landscape. Currently, the U.S. lacks a formal, regulated PAL framework for any allergen, including gluten. While the FDA requires the disclosure of wheat as a major allergen, it does not hold barley and rye to the same standard.

The Legislative Gap

This discrepancy is a significant source of risk. Ingredients like malt extract, brewer’s yeast, and barley-derived flavorings often slip through the cracks of consumer awareness because they are not required to be labeled with the same clarity as wheat.

The Foundation’s Call to Action

The Celiac Disease Foundation is currently leveraging the Codex progress to urge the FDA to take three specific actions:

1. Adopt the 4 mg Reference Dose: The Foundation has submitted formal comments to the FDA, requesting that the agency use the FAO/WHO-backed reference dose as the foundation for a U.S.-specific precautionary labeling standard.
2. Harmonize Barley and Rye Requirements: The Foundation continues to lobby for the inclusion of barley and rye under major allergen disclosure requirements, mirroring the rules currently applied to wheat.
3. Ensure Regulatory Consistency: The Foundation warns against any framework that creates contradictory signals. For instance, any new PAL guidance must not conflict with the existing 20 ppm gluten-free rule, ensuring that consumers are not confused by overlapping or competing safety messages.

Looking Ahead

While international standards like those set by Codex do not automatically become U.S. law, they create a global benchmark that the FDA can no longer ignore. By aligning with international consensus, the U.S. can ensure that its food safety policies remain evidence-based and globally competitive.

For the millions of Americans living with celiac disease, the road ahead involves ongoing advocacy to ensure these international successes translate into tangible domestic change. The scientific foundation is now stronger than it has ever been, and the goal remains clear: a marketplace where labels are not just warnings, but reliable, transparent, and protective tools that allow every individual to eat with confidence. As the FDA reviews its own rulemaking pathways, the Celiac Disease Foundation remains committed to ensuring that the voices of those affected by celiac disease continue to drive the future of food safety.